Correlation Engine 2.0
Clear Search sequence regions

  • adults (1)
  • dabigatran (10)
  • half life (1)
  • humans (1)
  • patients (1)
  • renal function (1)
  • stroke (1)
  • warfarin (1)
  • Sizes of these terms reflect their relevance to your search.

    Dabigatran etexilate (DE) was approved by the FDA in 2010 to reduce the risk of stroke and systemic embolism in adults with Non-valvular Atrial Fibrillation (NVAF). Compared with warfarin, a traditional anticoagulant drug, DE exhibits a shorter half-life, improved dose-effect relationship, fewer food and drug interactions, and can be taken orally without monitoring the conventional coagulation index. DE can also prevent or reduce the severity of adverse events, such as attenuated drug efficacy or bleeding. It is convenient for patients to take DE due to low levels of individual variation. This review aims to application of Dabigatran etexilate in specific populations. Fifty-five papers were included in the review. We review the pharmacological mechanisms, pharmacokinetics and drug interactions, as well as the application of DE for different clinical populations, and provide clinical guidelines. When using DE, one should consider the risk of bleeding, age, renal function, drug interactions, and other factors. Copyright© Bentham Science Publishers; For any queries, please email at


    Delai Xu, Cujin Su, Jie Pan. Advances and Application of a Novel Oral Anticoagulant in Specific Populations: Dabigatran Etexilate. Current drug metabolism. 2020;21(2):106-111

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 30317993

    View Full Text